Valuation: Tasly Pharmaceutical Group Co., Ltd

Market Cap 2.1TCr 314Cr 285.99Cr 263.52Cr 239.71Cr 449.71Cr 29TCr 472.63Cr 3.21TCr 1.27TCr 16TCr 1.18TCr 1.15TCr 50TCr P/E 2026 *
16.2x
P/E 2027 * 13.7x
Enterprise Value 1.91TCr 286.66Cr 261.09Cr 240.58Cr 218.84Cr 410.56Cr 27TCr 431.49Cr 2.93TCr 1.16TCr 14TCr 1.08TCr 1.05TCr 46TCr EV / Sales 2026 *
2.25x
EV / Sales 2027 * 1.66x
Free-Float
47.06%
Yield 2026 *
2.63%
Yield 2027 * 3.15%
1 day-1.75%
1 week+0.36%
Current month+1.52%
1 month-0.57%
3 months-9.31%
6 months-1.47%
Current year-6.90%
1 week 13.93
Extreme 13.93000000
14.53
1 month 13.48
Extreme 13.48
14.59
Current year 12.9
Extreme 12.9
16.24
1 year 12.9
Extreme 12.9
16.24
3 years 12.24
Extreme 12.24
18
5 years 9.2
Extreme 9.2
18
10 years 9.2
Extreme 9.2
34.22
Manager TitleAgeSince
Chief Executive Officer 54 08/05/2024
Director of Finance/CFO 49 09/07/2018
Chief Investment Officer 45 01/05/2025
Director TitleAgeSince
Director/Board Member 72 02/06/2021
Chairman 54 10/08/2026
Director/Board Member 59 08/05/2024
Change 5-day change 1-year change 3-year change Capi.($)
-1.75%+0.36%-8.06%-6.59% 314Cr
-0.30%-6.68%+29.12%+125.42% 1,20000Cr
+1.25%-5.35%+33.19%+80.42% 65TCr
+0.94%-2.99%+24.73%+106.93% 51TCr
-0.60%-1.95%+27.26%+67.32% 38TCr
+0.69%-9.50%+40.80%+30.23% 33TCr
+0.41%-4.70%+27.23%+51.59% 29TCr
+0.81%-4.08%-1.74%+32.71% 27TCr
-0.15%-6.45%+29.63%+64.18% 24TCr
-0.06%-0.98%+33.15%+118.99% 21TCr
Average +0.16%-4.53%+23.53%+67.12% 41TCr
Weighted average by Cap. +0.40%-5.19%+28.01%+87.42%

Financials

2026 *2027 *
Net sales 851.97Cr 127.63Cr 116.25Cr 107.11Cr 97Cr 182.79Cr 12TCr 192.11Cr 1.3TCr 518.15Cr 6.46TCr 478.87Cr 468.78Cr 20TCr 919.7Cr 137.78Cr 125.49Cr 115.63Cr 105.18Cr 197.33Cr 13TCr 207.39Cr 1.41TCr 559.34Cr 6.97TCr 516.95Cr 506.05Cr 22TCr
Net income 129.43Cr 19Cr 18Cr 16Cr 15Cr 28Cr 1.8TCr 29Cr 198.05Cr 79Cr 980.66Cr 73Cr 71Cr 3.08TCr 152.39Cr 23Cr 21Cr 19Cr 17Cr 33Cr 2.11TCr 34Cr 233.18Cr 93Cr 1.15TCr 86Cr 84Cr 3.62TCr
Net Debt -182.47Cr -27Cr -25Cr -23Cr -21Cr -39Cr -2.53TCr -41Cr -279.21Cr -110.97Cr -1.38TCr -102.56Cr -100.4Cr -4.34TCr -567.52Cr -85Cr -77Cr -71Cr -65Cr -121.76Cr -7.87TCr -127.97Cr -868.41Cr -345.15Cr -4.3TCr -318.99Cr -312.27Cr -13TCr
Projected Income Statement - Annual - Tasly Pharmaceutical Group Co., Ltd
Logo Tasly Pharmaceutical Group Co., Ltd
Tasly Pharmaceutical Group Co Ltd is a China-based company principally engaged in the manufacture and distribution of pharmaceutical products. The Company's main businesses include the manufacture and sales of traditional Chinese medicines, chemical preparations, chemical raw materials and biological medicines. The Company's main products include Compound Danshen Dropping Pills, Yangxuenao Granules, Yangxuenao Pills, Qishen Yiqi Dropping Pills, Diqing and Shuilinjia. Its products are used to treat cardiovascular and cerebrovascular diseases, tumors, colds, fevers and liver diseases. The Company mainly distributes its products in the domestic market.
Employees
10,563
Date Price Change Volume
20/26/20 CN¥14.03 -1.75% 1,33,42,579
19/26/19 CN¥14.28 -0.56% 95,55,753
18/26/18 CN¥14.36 +0.21% 1,25,77,226
17/26/17 CN¥14.33 -0.42% 1,43,94,860
16/26/16 CN¥14.39 +2.93% 2,18,53,322
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Tasly Pharmaceutical Group Co., Ltd
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
14.03CNY
Average target price
16.73CNY
Spread / Average Target
+19.26%
  1. Stock Market
  2. Stocks
  3. 600535 Stock